- Home
- ARGX vs CCEP Comparison
ARGX vs CCEP Comparison
Compare ARGX & CCEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- CCEP
- Stock Information
- Founded
- ARGX 2008
- CCEP 1986
- Country
- ARGX Netherlands
- CCEP United Kingdom
- Employees
- ARGX N/A
- CCEP N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- CCEP Beverages (Production/Distribution)
- Sector
- ARGX Health Care
- CCEP Consumer Staples
- Exchange
- ARGX Nasdaq
- CCEP Nasdaq
- Market Cap
- ARGX 40.4B
- CCEP 37.9B
- IPO Year
- ARGX 2017
- CCEP 1987
- Fundamental
- Price
- ARGX $591.87
- CCEP $87.03
- Analyst Decision
- ARGX Strong Buy
- CCEP Buy
- Analyst Count
- ARGX 20
- CCEP 7
- Target Price
- ARGX $682.00
- CCEP $88.83
- AVG Volume (30 Days)
- ARGX 314.1K
- CCEP 3.7M
- Earning Date
- ARGX 05-08-2025
- CCEP 02-14-2025
- Dividend Yield
- ARGX N/A
- CCEP 2.45%
- EPS Growth
- ARGX N/A
- CCEP N/A
- EPS
- ARGX 12.78
- CCEP 3.19
- Revenue
- ARGX $2,248,205,000.00
- CCEP $21,159,540,332.00
- Revenue This Year
- ARGX $57.86
- CCEP $7.33
- Revenue Next Year
- ARGX $31.90
- CCEP $3.82
- P/E Ratio
- ARGX $43.78
- CCEP $27.29
- Revenue Growth
- ARGX 77.22
- CCEP 11.67
- 52 Week Low
- ARGX $352.77
- CCEP $65.94
- 52 Week High
- ARGX $678.21
- CCEP $88.39
- Technical
- Relative Strength Index (RSI)
- ARGX 42.34
- CCEP 62.74
- Support Level
- ARGX $582.07
- CCEP $83.21
- Resistance Level
- ARGX $598.06
- CCEP $87.44
- Average True Range (ATR)
- ARGX 13.05
- CCEP 1.56
- MACD
- ARGX -0.35
- CCEP 0.12
- Stochastic Oscillator
- ARGX 33.69
- CCEP 92.56
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About CCEP Coca-Cola Europacific Partners plc
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe (80% of 2023 revenue and EBIT) and Australasia (20%).In 2023, CCEP sold 3.3 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume. Coke's largest bottler, Coca-Cola Femsa sold 4 billion unit cases (12%), and the third-largest, Coca-Cola HBC, serving Eastern Europe and North Africa, sold 2.8 billion unit cases (8%).TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.